{"id":"W4407567762","doi":"10.1007/s13555-025-01357-7","title":"Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy","year":2025,"lang":"en","type":"review","venue":"Dermatology and Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; SKiN Health","funders":"Sanofi Genzyme; Genentech; Glenmark Pharmaceuticals; Pfizer; Biogen; Incyte; Moderna; UCB Pharma; Valeant Pharmaceuticals International; Argenx; Kiniksa Pharmaceuticals; Ribon Therapeutics; Sun Pharma; Dermira; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; LEO Pharma; Gilead Sciences; Bausch Health; L'Oreal USA; Sanofi; Celgene; GlaxoSmithKline; Amgen; Galderma; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atopic dermatitis; Medicine; Meta-analysis; Systemic therapy; Dermatology; Internal medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02224245,0.002634884,0.01307718,0.004670171,0.0005156499,0.003135936,0.001743067,0.001668274,0.003437659],"category_scores_gemma":[0.03315543,0.001226363,0.04860415,0.003890284,0.0006513468,0.001303237,0.001353686,0.001735401,0.000267644],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002127557,"about_ca_system_score_gemma":0.002001521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004794976,"about_ca_topic_score_gemma":0.007845745,"domain_scores_codex":[0.9840978,0.0110489,0.001952335,0.001612388,0.0009796413,0.0003088544],"domain_scores_gemma":[0.9761549,0.0184618,0.003271621,0.0009551099,0.0008505948,0.0003058805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.005653739,0.00003086971,0.005513485,0.05060895,0.9276785,0.00005194631,0.00002913251,0.001092236,0.0001563337,0.0001041831,0.0003405722,0.008740101],"study_design_scores_gemma":[0.00215207,0.000387274,0.003852278,0.003695324,0.9880774,0.00005225326,0.00001752481,0.0005679141,0.0001009187,0.0003496419,0.0007308509,0.0000166288],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.03232471,0.9617202,0.001975827,0.0006944259,0.0003780571,0.0004934866,0.001537785,0.0000877593,0.0007878146],"genre_scores_gemma":[0.7247387,0.2649499,0.004696138,0.001349503,0.0005431616,0.001430478,0.001682871,0.00007839341,0.0005308582],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.02224245,"threshold_uncertainty_score":0.1176308,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07042809012567897,"score_gpt":0.3536065433075238,"score_spread":0.2831784531818449,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}